je.st
news
Amarantus Receives Orphan Drug Designation For Eltoprazine
2016-02-11 06:24:55| drugdiscoveryonline News Articles
Amarantus BioScience Holdings, Inc.(OTCQB: AMBS),a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced that it has received orphan drug designation from the US FDA for Eltoprazine in the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID).
Tags: drug
receives
designation
orphan
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||